कंपनी का अवलोकन
Addex Therapeutics Ltd is a biotechnology entity headquartered in Switzerland dedicated to the discovery, development, and commercialization of small-molecule pharmaceutical products specifically targeting neurological disorders. The company's strategic focus lies in the identification of G-protein coupled receptors and enzymes, with its lead program, Dipraglurant, currently advancing through phase 1 clinical trials. Operating within the broader healthcare sector and the specific biotechnology industry, the firm represents a niche player in specialized drug discovery rather than a diversified pharmaceutical conglomerate. With a market capitalization of $8.61M and an annual revenue of $158,538 supported by a workforce of just 2 employees, the company operates at a very early stage of development. These valuation and revenue figures indicate that Addex Therapeutics is a micro-cap entity with minimal operational scale, suggesting that its current financial position relies heavily on future clinical progress and external capital infusion rather than established commercial sales streams or significant existing market share.
वित्तीय स्वास्थ्य
The company reported a revenue of $158,538 over the trailing twelve months, yet it recorded a net income of $-6,198,837, revealing a significant structural gap where operating costs and research expenses vastly exceed current income generation. This disparity between low revenue and substantial net losses highlights a cost structure typical of pre-commercial biotechnology firms where heavy expenditures are directed toward clinical trials and R&D before product launch. Free cash flow stood at $-599,840, indicating that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility without ongoing equity financing or strategic partnerships. All three margin metrics reflect this developmental phase: the gross margin is 0.0%, the operating margin is -1403.6%, and the profit margin is 0.0%, collectively indicating that the company has not yet achieved profitability or positive contribution margins from its sales. In terms of leverage, the company holds $2.19M in cash against $36,549 in debt, resulting in a debt-to-equity ratio of 0.61, which suggests a relatively low level of debt burden despite the cash burn. The current ratio of 2.01 indicates that the company possesses sufficient short-term assets to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Finally, the return on equity is -72.8% and the return on assets is -15.9%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, consistent with the high-risk profile of a company in early-stage clinical development.
मूल्यांकन आकलन
Trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed at -139.82, a negative figure that implies the market is pricing in expectations of future profitability that have not yet materialized in current financial statements. The price-to-book ratio stands at 109.36, indicating that the market values the company at a premium significantly above its net asset value, reflecting the potential worth of its intellectual property and pipeline rather than tangible assets. Additionally, the price-to-sales ratio is 54.33 and the EV/EBITDA is -330.83, suggesting that traditional valuation multiples are distorted by the lack of profitability and that investors are valuing the firm based on its growth potential and clinical assets rather than current cash flows. The stock has traded between a 52-week low of $5.57 and a high of $12.05, meaning the current price sits within a range that reflects high volatility typical of small-cap biotech stocks. The beta value of 1.86 indicates that the stock's price volatility is substantially higher than the broader market, moving with greater intensity during periods of market stress or sector-specific news.
Growth & Income
The revenue growth year-over-year is -15.0%, while earnings growth is N/A due to the absence of positive earnings, implying that the company is currently shrinking in terms of top-line revenue generation rather than expanding its commercial footprint. Since the company is not a dividend payer, it does not distribute a dividend yield or a payout ratio, meaning that all available earnings, which are currently negative, are theoretically available for reinvestment if profitability were achieved. Instead of paying dividends, the company reinvests its limited resources into its clinical programs and operational scaling, a common strategy for biotechnology firms aiming to reach commercial milestones before returning capital to shareholders. The overall growth and income profile for Addex Therapeutics is characterized by negative revenue trajectory and a complete absence of dividend income, positioning the asset as a high-risk, high-potential equity dependent entirely on the successful advancement of its Dipraglurant program and future market entry.